Ultragenyx Pharmaceutical Inc. (RARE) 34.04 $RARE
Ultragenyx Reports First Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Mon May 12, 8:15AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the first quarter ended March 31, 2014.
Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting
GlobeNewswire - Wed Apr 30, 6:30PM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of detailed results from a 48-week Phase 2 clinical study of sialic acid extended-release (SA-ER, UX001) tablets in 47 patients with hereditary inclusion body myopathy (HIBM; also known by its new name as GNE myopathy), a rare, progressive muscle-wasting disease. SA-ER is designed to replace the deficient sialic acid substrate in patients with HIBM.
Sialic Acid Extended-Release Phase 2 Study Data to be Presented at American Academy of Neurology Annual Meeting
GlobeNewswire - Mon Apr 28, 10:06AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the upcoming presentation of data from a Phase 2 clinical study of sialic acid extended-release (SA-ER, UX001) tablets in hereditary inclusion body myopathy (HIBM; also known by its new name as GNE myopathy). HIBM is a rare, progressive muscle-wasting disease, and SA-ER is designed to replace the deficient sialic acid substrate in patients with HIBM.
Clinical Trial Results Presentation and Publication, and Upcoming Exhibit - Analyst Notes on Gilead Sciences, Agios, Mindray, BG Medicine, and Ultragenyx
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Mindray Medical International Limited (NYSE: MR), BG Medicine, Inc. (NASDAQ: BGMD), and Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
'Fast Money' Recap: S&P Snapback
at The Street - Wed Apr 09, 4:00AM CDT
The trading panel discussed whether investors can trust this latest rlly.
Ultragenyx (RARE) Jumps: Stock Rises 7.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:46AM CDT
Ultragenyx was a big mover last session, with shares rising 7% on the day.
Ultragenyx Announces Preliminary Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
GlobeNewswire - Thu Mar 27, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of preliminary data from the Phase 1/2 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of mucopolysaccharidosis 7 (MPS 7, Sly syndrome).
The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014
GlobeNewswire - Thu Mar 27, 7:50AM CDT
74 New U.S. Listings Including 45 IPOs
Ultragenyx Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 24, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and business highlights for the fourth quarter and year ended December 31, 2013.
Ultragenyx to Present at the BioCentury Future Leaders in the Biotech Industry Conference
GlobeNewswire - Fri Mar 21, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference on March 28, 2014 at 2:00pm ET at the Millennium Broadway Hotel & Conference Center in New York.
Biotechs Tripling at IPO! Sign of Biotech Bubble?
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 13, 6:24PM CDT
The proverbial biotech IPO window has been open for some time now, but it appears to have grown to the size of an airplane hangar door, allowing almost any biotech to go public at astonishingly high valuations. Ultragenyx Pharmaceutical doubled...
Ultragenyx Announces First Patient Enrolled in Phase 2 Study of Triheptanoin in Glucose Transporter Type-1 Deficiency Syndrome
GlobeNewswire - Tue Mar 11, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the first patient enrolled in the Phase 2 study of triheptanoin (UX007) for the treatment of glucose transporter type-1 deficiency syndrome (Glut1 DS), at Columbia University. Glut1 DS, also known as De Vivo disease, is a rare, severely debilitating disease characterized by seizures, developmental delay, and movement disorder.
Ultragenyx to Present at Cowen and Company 34th Annual Health Care Conference in Boston
GlobeNewswire - Wed Feb 26, 8:22AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Cowen and Company 34 Annual Health Care Conference on March 5, 2014 at 11:20am ET at the Boston Marriott Copley Place.
Ultragenyx Jumps on Positive Patient Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 3:10PM CST
Ultragenyx Pharmaceutical Inc. will be presenting encouraging data on its mucopolysaccharidosis 7 candidate, rhGUS.
Ultragenyx Announces Presentation of Data From a Single Patient Treated With Recombinant Human Beta-Glucuronidase at 10th Annual World Lysosomal Disease Network Symposium
GlobeNewswire - Wed Feb 12, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced data presentations from a single patient treated with recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of mucopolysaccharidosis 7 (MPS 7, Sly syndrome).
Ultragenyx Announces Initiation of Phase 2 Study for Patients with Long-Chain Fatty Acid Oxidation Disorders
GlobeNewswire - Tue Feb 11, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the first patient has been enrolled in an open-label Phase 2 study to assess safety and clinical effects of triheptanoin, also known as UX007, in patients severely affected by long-chain fatty acid oxidation disorders (LC-FAOD). LC-FAOD are a group of autosomal recessive genetic disorders characterized by metabolic deficiencies in which the body is unable to break down and convert long chain fatty acids into energy.
Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors
GlobeNewswire - Thu Feb 06, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of Clay B. Siegall, Ph.D. and Matthew Fust to the company's Board of Directors effective January 30, 2014. Dr. Siegall, currently President, Chief Executive Officer and Chairman of the Board of Seattle Genetics, Inc., and Mr. Fust, formerly Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc. will serve as independent directors for Ultragenyx. With these additions, Ultragenyx extends gratitude and appreciation for the counsel provided by Mr. Ben Auspitz, who has resigned from his position on the Board effective January 30, 2014.
Ultragenyx Announces Closing of Initial Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Wed Feb 05, 10:15AM CST
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the closing of its initial public offering of 6,624,423 shares of common stock at an initial public offering price of $21.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 864,054 additional shares of common stock. All of the shares of common stock were offered by Ultragenyx. The company's common stock is listed on The NASDAQ Global Select Market under the ticker symbol "RARE." Ultragenyx estimates net proceeds from the offering to be approximately $126.4 million, after deducting underwriting discounts and commissions and estimated offering expenses.
IPO roundup: 6 companies go public Friday
By The Associated Press - AP - Fri Jan 31, 5:32PM CST
Six companies made their stock market debuts Friday as the IPO market revs up in 2014. Last year the market for initial public offerings boomed as stock markets rose, with major debuts from hotel owner Hilton Worldwide Holdings Inc., which raised $2.35 billion, and online messaging service Twitter Inc., which raised $2.1 billion.
Ultragenyx Reports First Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Mon May 12, 8:15AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the first quarter ended March 31, 2014.
Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting
GlobeNewswire - Wed Apr 30, 6:30PM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of detailed results from a 48-week Phase 2 clinical study of sialic acid extended-release (SA-ER, UX001) tablets in 47 patients with hereditary inclusion body myopathy (HIBM; also known by its new name as GNE myopathy), a rare, progressive muscle-wasting disease. SA-ER is designed to replace the deficient sialic acid substrate in patients with HIBM.
Sialic Acid Extended-Release Phase 2 Study Data to be Presented at American Academy of Neurology Annual Meeting
GlobeNewswire - Mon Apr 28, 10:06AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the upcoming presentation of data from a Phase 2 clinical study of sialic acid extended-release (SA-ER, UX001) tablets in hereditary inclusion body myopathy (HIBM; also known by its new name as GNE myopathy). HIBM is a rare, progressive muscle-wasting disease, and SA-ER is designed to replace the deficient sialic acid substrate in patients with HIBM.
Clinical Trial Results Presentation and Publication, and Upcoming Exhibit - Analyst Notes on Gilead Sciences, Agios, Mindray, BG Medicine, and Ultragenyx
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Mindray Medical International Limited (NYSE: MR), BG Medicine, Inc. (NASDAQ: BGMD), and Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
'Fast Money' Recap: S&P Snapback
at The Street - Wed Apr 09, 4:00AM CDT
The trading panel discussed whether investors can trust this latest rlly.
Ultragenyx (RARE) Jumps: Stock Rises 7.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:46AM CDT
Ultragenyx was a big mover last session, with shares rising 7% on the day.
Ultragenyx Announces Preliminary Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
GlobeNewswire - Thu Mar 27, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of preliminary data from the Phase 1/2 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of mucopolysaccharidosis 7 (MPS 7, Sly syndrome).
The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014
GlobeNewswire - Thu Mar 27, 7:50AM CDT
74 New U.S. Listings Including 45 IPOs
Ultragenyx Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 24, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and business highlights for the fourth quarter and year ended December 31, 2013.
Ultragenyx to Present at the BioCentury Future Leaders in the Biotech Industry Conference
GlobeNewswire - Fri Mar 21, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference on March 28, 2014 at 2:00pm ET at the Millennium Broadway Hotel & Conference Center in New York.
Biotechs Tripling at IPO! Sign of Biotech Bubble?
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 13, 6:24PM CDT
The proverbial biotech IPO window has been open for some time now, but it appears to have grown to the size of an airplane hangar door, allowing almost any biotech to go public at astonishingly high valuations. Ultragenyx Pharmaceutical doubled...
Ultragenyx Announces First Patient Enrolled in Phase 2 Study of Triheptanoin in Glucose Transporter Type-1 Deficiency Syndrome
GlobeNewswire - Tue Mar 11, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the first patient enrolled in the Phase 2 study of triheptanoin (UX007) for the treatment of glucose transporter type-1 deficiency syndrome (Glut1 DS), at Columbia University. Glut1 DS, also known as De Vivo disease, is a rare, severely debilitating disease characterized by seizures, developmental delay, and movement disorder.
Ultragenyx to Present at Cowen and Company 34th Annual Health Care Conference in Boston
GlobeNewswire - Wed Feb 26, 8:22AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Cowen and Company 34 Annual Health Care Conference on March 5, 2014 at 11:20am ET at the Boston Marriott Copley Place.
Ultragenyx Jumps on Positive Patient Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 3:10PM CST
Ultragenyx Pharmaceutical Inc. will be presenting encouraging data on its mucopolysaccharidosis 7 candidate, rhGUS.
Ultragenyx Announces Presentation of Data From a Single Patient Treated With Recombinant Human Beta-Glucuronidase at 10th Annual World Lysosomal Disease Network Symposium
GlobeNewswire - Wed Feb 12, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced data presentations from a single patient treated with recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of mucopolysaccharidosis 7 (MPS 7, Sly syndrome).
Ultragenyx Announces Initiation of Phase 2 Study for Patients with Long-Chain Fatty Acid Oxidation Disorders
GlobeNewswire - Tue Feb 11, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the first patient has been enrolled in an open-label Phase 2 study to assess safety and clinical effects of triheptanoin, also known as UX007, in patients severely affected by long-chain fatty acid oxidation disorders (LC-FAOD). LC-FAOD are a group of autosomal recessive genetic disorders characterized by metabolic deficiencies in which the body is unable to break down and convert long chain fatty acids into energy.
Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors
GlobeNewswire - Thu Feb 06, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of Clay B. Siegall, Ph.D. and Matthew Fust to the company's Board of Directors effective January 30, 2014. Dr. Siegall, currently President, Chief Executive Officer and Chairman of the Board of Seattle Genetics, Inc., and Mr. Fust, formerly Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc. will serve as independent directors for Ultragenyx. With these additions, Ultragenyx extends gratitude and appreciation for the counsel provided by Mr. Ben Auspitz, who has resigned from his position on the Board effective January 30, 2014.
Ultragenyx Announces Closing of Initial Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Wed Feb 05, 10:15AM CST
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the closing of its initial public offering of 6,624,423 shares of common stock at an initial public offering price of $21.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 864,054 additional shares of common stock. All of the shares of common stock were offered by Ultragenyx. The company's common stock is listed on The NASDAQ Global Select Market under the ticker symbol "RARE." Ultragenyx estimates net proceeds from the offering to be approximately $126.4 million, after deducting underwriting discounts and commissions and estimated offering expenses.
IPO roundup: 6 companies go public Friday
By The Associated Press - AP - Fri Jan 31, 5:32PM CST
Six companies made their stock market debuts Friday as the IPO market revs up in 2014. Last year the market for initial public offerings boomed as stock markets rose, with major debuts from hotel owner Hilton Worldwide Holdings Inc., which raised $2.35 billion, and online messaging service Twitter Inc., which raised $2.1 billion.
